Scandinavian ChemoTech continues its launch in Africa by receiving a new agreement and orders

ChemoTech is expanding in Africa by signing a collaboration agreement for clinical validation and distribution with Femaug Logistics and Services Ltd (FLS) in Nigeria. In conjunction with this agreement, ChemoTech will receive two orders for a total value of EUR 50,000.

The agreement is intended to initially secure a collaboration where leading doctors and decision-makers in Nigeria receive education and the opportunity to gather important clinical data for continued launch in the country and in the economic West African property, EKOWAS, a region with nearly 400 million inhabitants.

“It’s extremely exciting that we can now begin a long-term endeavour in West Africa with the aim of creating important clinical evidence and relationships with leading oncologists. We start our establishment process in Nigeria and ECOWAS with two orders, however, it is only after the clinical evidence from studies or clinical evaluation that D-EECT will be able to be launched on a larger scale within Nigeria's public healthcare system”- Mohan Frick, CEO

ChemoTech's co-founder Dr. Göran Hellers, who has long experience of establishing medical technology in oncology in ECOWAS, will together with FLS be responsible for ChemoTech's establishment work in the region.

Femaug Logistics and Services Ltd is a Nigerian based marketing and distribution company that specialises in the marketing and distribution of medical devices and services.

The CEO and Co-Founder Temitope Akintaju and his partner Femi Israel has extensive experiences in medical technology and in Nigerian and Swedish business relations.

 

 

Swedish translation: 
 

Scandinavian ChemoTech fortsätter lanseringsarbetet i Afrika genom ett nytt avtal och order

ChemoTech expanderar i Afrika genom att signera ett samarbetsavtal för klinisk validering och distribution med Femaug Logistics and Services Ltd (FLS) i Nigeria. ChemoTech får i samband med detta avtal två order som uppgår till ett totalt värde av 50,000 EURO.

Avtalet är tänkt att initialt säkerställa ett samarbete där ledande läkare och beslutsfattare i Nigeria får utbildning och möjlighet att samla in viktig kliniska data för fortsatt lansering i landet och i den ekonomiska västafrikanska egenskapen, EKOWAS, en region med närmre 400 miljoner invånare.

”Det känns oerhört spännande att vi nu kan påbörja ett långsiktigt arbete i Västafrika i syfte att skapa viktiga kliniska evidens och relationer med ledande onkologer. Vi startar vår etableringsprocess i Nigeria och ECOWAS med två order, dock är det först efter det kliniska underlaget från studier eller kliniska utvärdering som D-EECT i större skala kommer kunna lanseras inom Nigerias offentliga sjukvård” - Mohan Frick, CEO
 

ChemoTechs medgrundare Dr. Göran Hellers, som har lång erfarenhet från att etablera medicinteknik inom onkologi i ECOWAS, kommer tillsammans med FLS att ansvara för ChemoTechs etableringsarbete i regionen.

Femaug Logistics and Services Ltd är ett marknadsförings- och distributionsföretag baserat i Nigeria, specialiserat på marknadsföring och distribution av medicintekniska produkter och tjänster. VD:n och medgrundaren Temitope Akintaju och hans partner Femi Israel har tillsammans omfattande erfarenheter inom medicinsk teknik samt i nigerianska och svenska affärsrelationer.

 

For more information, please contact:

Mohan Frick, Co-Founder and CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Wednesday March 04th 2020 at 11.30 (CET).

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe